Esteve Pharmaceuticals has been granted a patent for novel immunogens based on overlapping peptides (OLPs) for preventing and treating AIDS and related diseases. The patent includes immunogenic fusion polypeptides containing specific amino acid sequences. GlobalData’s report on Esteve Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Esteve Pharmaceuticals SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Esteve Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Esteve Pharmaceuticals's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Aids prevention and treatment vaccine using novel immunogens

Source: United States Patent and Trademark Office (USPTO). Credit: Esteve Pharmaceuticals SA

A recently granted patent (Publication Number: US11919926B2) discloses an immunogenic fusion polypeptide comprising two or more amino acid sequences, as specified in the claims. The fusion polypeptide includes specific amino acid sequences from SEQ ID NOs: 1-16, with variations in the combinations of sequences allowed. Additionally, the patent outlines the inclusion of an N-terminal signal peptide, such as GMCSF, MCP-3, CATE, or LAMP1, to enhance the immunogenic properties of the fusion polypeptide. The use of amino acid linkers of varying lengths and compositions between the sequences is also detailed to optimize the structure and function of the fusion polypeptide.

Furthermore, the patent covers the application of the immunogenic fusion polypeptide in a cell, vaccine, or kit for treating or preventing HIV infections or associated diseases. The method involves administering the fusion polypeptide to elicit an immune response against HIV in human subjects, potentially addressing conditions like AIDS, ARC, or HIV opportunistic diseases. Sequential administration of different fusion polypeptides is also described as a strategy to enhance the immune response against HIV. Overall, the patent provides a detailed framework for utilizing the immunogenic fusion polypeptide in therapeutic interventions related to HIV infections, highlighting its potential in advancing treatment and prevention strategies in this critical area of healthcare.

To know more about GlobalData’s detailed insights on Esteve Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies